Tags

Type your tag names separated by a space and hit enter

The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Group.
Ann Hematol. 2017 Feb; 96(2):279-288.AH

Abstract

This study compared 6-year follow-up data from patients undergoing reduced-intensity conditioning (RIC) transplantation with an HLA-matched related donor (MRD), an HLA-matched unrelated donor (MUD), or an HLA-haploidentical donor (HID) for leukemia. Four hundred and twenty-seven patients from the China RIC Cooperative Group were enrolled, including 301 in the MRD, 79 in the HID, and 47 in the MUD groups. The conditioning regimen involved fludarabine combined with anti-lymphocyte globulin and cyclophosphamide. Graft-versus-host disease (GVHD) prophylaxis was administered using cyclosporin A (CsA) and mycophenolate mofetil (MMF). Four hundred and nineteen patients achieved stable donor chimerism. The incidence of stage II-IV acute GVHD in the HID group was 44.3 %, significantly higher than that in the MRD (23.6 %) and MUD (19.1 %) groups. The 1-year transplantation-related mortality (TRM) rates were 44.3, 17.6, and 21.3, respectively. Event-free survival (EFS) at 6 years in the HID group was 36.7 %, significantly lower than that of the MRD and MUD groups (59.1 and 66.0 %, P < 0.001 and P = 0.001, respectively). For advanced leukemia, the relapse rate of the HID group was 18.5 %, lower than that of the MRD group (37.5 %, P = 0.05), but the EFS at 6 years was 31.7 and 30.4 % (P > 0.05), respectively. RIC transplantation with MRD and MUD had similar outcome in leukemia which is better than that with HID. RIC transplantation with HID had lower relapsed with higher TRM and GVHD rate, particularly in advanced leukemias. RIC transplantation with MRD and MUD had similar outcomes in leukemia and they were better than those with HID. RIC transplantation with HID had a lower relapse rate but higher TRM and GVHD rates, particularly in cases of advanced leukemia.

Authors+Show Affiliations

Department of Hematology and Transplantation, Affiliated Hospital of the Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China.Department of Hematology and Transplantation, Affiliated Hospital of the Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China.Second Hospital of Shanxi Medical University, Taiyuan, China.Chang Hai Hospital of Shanghai Second Military Medical University, Shanghai, China.Affiliated Hospital of Zhejiang University, Hangzhou, China.Tang-Du Hospital of Fourth Military Medical University, Xi'an, China.Affiliated Hospital of Suzhou University, Suzhou, China.Affiliated Zhongda Hospital of Southeast University, Nanjing, China.Lanzhou General Hospital in Lanzhou Military Area Command, Lanzhou, China.201 Hospital Shenyang, Shenyang, China.Second Artillery General Hospital, Beijing, China.Second Artillery General Hospital, Beijing, China.Department of Hematology and Transplantation, Affiliated Hospital of the Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China.Department of Hematology and Transplantation, Affiliated Hospital of the Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China.Department of Hematology and Transplantation, Affiliated Hospital of the Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China.Department of Hematology and Transplantation, Affiliated Hospital of the Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China.Department of Hematology and Transplantation, Affiliated Hospital of the Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China.Department of Hematology and Transplantation, Affiliated Hospital of the Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China.Department of Hematology and Transplantation, People's Hospital Under Beijing University, Beijing, 100044, China. huangxiaojun@bjmu.edu.cn.Department of Hematology and Transplantation, Affiliated Hospital of the Academy of Military Medical Sciences, 8 Dongdajie, Beijing, 100071, China. huishengai@163.com.

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

27864604

Citation

Yu, Chang-Lin, et al. "The Long-term Outcome of Reduced-intensity Allogeneic Stem Cell Transplantation From a Matched Related or Unrelated Donor, or Haploidentical Family Donor in Patients With Leukemia: a Retrospective Analysis of Data From the China RIC Cooperative Group." Annals of Hematology, vol. 96, no. 2, 2017, pp. 279-288.
Yu CL, Zheng-Dong , Qiao ZH, et al. The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Group. Ann Hematol. 2017;96(2):279-288.
Yu, C. L., Zheng-Dong, ., Qiao, Z. H., Wang, J. M., Huang-He, ., Liang, Y. M., Wu, D. P., Chen, B. A., Bai-Hai, ., Shi, B. F., Sun, W. J., Qiao, J. X., Guo, M., Qiao, J. H., Sun, Q. Y., Hu, K. X., Huang, Y. J., Zuo, H. L., Huang, X. J., & Ai, H. S. (2017). The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Group. Annals of Hematology, 96(2), 279-288. https://doi.org/10.1007/s00277-016-2864-y
Yu CL, et al. The Long-term Outcome of Reduced-intensity Allogeneic Stem Cell Transplantation From a Matched Related or Unrelated Donor, or Haploidentical Family Donor in Patients With Leukemia: a Retrospective Analysis of Data From the China RIC Cooperative Group. Ann Hematol. 2017;96(2):279-288. PubMed PMID: 27864604.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Group. AU - Yu,Chang-Lin, AU - Zheng-Dong,, AU - Qiao,Zhen-Hua, AU - Wang,Jian-Min, AU - Huang-He,, AU - Liang,Ying-Min, AU - Wu,De-Pei, AU - Chen,Bao-An, AU - Bai-Hai,, AU - Shi,Bao-Fu, AU - Sun,Wan-Jun, AU - Qiao,Jun-Xiao, AU - Guo,Mei, AU - Qiao,Jian-Hui, AU - Sun,Qi-Yun, AU - Hu,Kai-Xun, AU - Huang,Ya-Jing, AU - Zuo,Hong-Li, AU - Huang,Xiao-Jun, AU - Ai,Hui-Sheng, Y1 - 2016/11/18/ PY - 2016/04/09/received PY - 2016/10/20/accepted PY - 2016/11/20/pubmed PY - 2017/2/2/medline PY - 2016/11/20/entrez KW - Allogeneic stem cell transplantation KW - China RIC Cooperative Group KW - Leukemia SP - 279 EP - 288 JF - Annals of hematology JO - Ann. Hematol. VL - 96 IS - 2 N2 - This study compared 6-year follow-up data from patients undergoing reduced-intensity conditioning (RIC) transplantation with an HLA-matched related donor (MRD), an HLA-matched unrelated donor (MUD), or an HLA-haploidentical donor (HID) for leukemia. Four hundred and twenty-seven patients from the China RIC Cooperative Group were enrolled, including 301 in the MRD, 79 in the HID, and 47 in the MUD groups. The conditioning regimen involved fludarabine combined with anti-lymphocyte globulin and cyclophosphamide. Graft-versus-host disease (GVHD) prophylaxis was administered using cyclosporin A (CsA) and mycophenolate mofetil (MMF). Four hundred and nineteen patients achieved stable donor chimerism. The incidence of stage II-IV acute GVHD in the HID group was 44.3 %, significantly higher than that in the MRD (23.6 %) and MUD (19.1 %) groups. The 1-year transplantation-related mortality (TRM) rates were 44.3, 17.6, and 21.3, respectively. Event-free survival (EFS) at 6 years in the HID group was 36.7 %, significantly lower than that of the MRD and MUD groups (59.1 and 66.0 %, P < 0.001 and P = 0.001, respectively). For advanced leukemia, the relapse rate of the HID group was 18.5 %, lower than that of the MRD group (37.5 %, P = 0.05), but the EFS at 6 years was 31.7 and 30.4 % (P > 0.05), respectively. RIC transplantation with MRD and MUD had similar outcome in leukemia which is better than that with HID. RIC transplantation with HID had lower relapsed with higher TRM and GVHD rate, particularly in advanced leukemias. RIC transplantation with MRD and MUD had similar outcomes in leukemia and they were better than those with HID. RIC transplantation with HID had a lower relapse rate but higher TRM and GVHD rates, particularly in cases of advanced leukemia. SN - 1432-0584 UR - https://www.unboundmedicine.com/medline/citation/27864604/The_long_term_outcome_of_reduced_intensity_allogeneic_stem_cell_transplantation_from_a_matched_related_or_unrelated_donor_or_haploidentical_family_donor_in_patients_with_leukemia:_a_retrospective_analysis_of_data_from_the_China_RIC_Cooperative_Group_ L2 - https://dx.doi.org/10.1007/s00277-016-2864-y DB - PRIME DP - Unbound Medicine ER -